Skip to main content

Alpelisib Side Effects

Medically reviewed by Last updated on May 13, 2024.

Applies to alpelisib: oral tablet.

Serious side effects of Alpelisib

Along with its needed effects, alpelisib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking alpelisib:

More common

Less common

Incidence not known

Other side effects of Alpelisib

Some side effects of alpelisib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to alpelisib: oral tablet.


Very common (10% or more): Lymphocyte count decreased (52%), hemoglobin decreased (42%), activated partial thromboplastin time (aPTT) prolonged (21%), platelet count decreased (14%)[Ref]


Uncommon (0.1% to 1%): Severe hypersensitivity (e.g., anaphylaxis, anaphylactic shock, dyspnea, flushing, rash, fever, tachycardia)[Ref]


Common (1% to 10%): Osteonecrosis of the jaw (ONJ)[Ref]


Very common (10% or more): Glucose increased (79%), hyperglycemia (65%), weight loss (27%), calcium (corrected) decreased (27%), glucose decreased (26%), potassium decreased (14%), albumin decreased (14%), magnesium decreased (11%)[Ref]


Very common (10% or more): Urinary tract infection (10%)[Ref]


Very common (10% or more): Gamma glutamyl transferase (GGT) increased (52%), alanine aminotransferase (ALT) increased (44%)[Ref]


Common (1% to 10%): Pneumonitis (including acute interstitial pneumonitis and interstitial lung disease)[Ref]


Very common (10% or more): Fatigue (42%), lipase increased (42%), edema peripheral (15%), pyrexia (14%)[Ref]


The most common adverse reactions including laboratory abnormalities (all Grades, incidence 20% or greater) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, GGT increased, nausea, ALT increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, activated partial thromboplastin time (aPTT) prolonged, and alopecia.[Ref]

Nervous system

Very common (10% or more): Headache (18%), dysgeusia/ageusia/hypogeusia (18%)[Ref]


Very common (10% or more): Creatinine increased (79%)[Ref]


Very common (10% or more): Rash (e.g., maculopapular, macular, generalized, papular, pruritic) (52%), alopecia (20%), pruritus (18%), dry skin/skin fissures/xerosis/xeroderma (18%)

Uncommon (0.1% to 1%): Stevens-Johnson syndrome (SJS), erythema multiforme (EM)[Ref]


Very common (10% or more): Diarrhea (58%), nausea (45%), stomatitis/aphthous ulcer/mouth ulceration (30%), vomiting (27%), mucosal inflammation (19%), abdominal pain/abdominal pain upper/abdominal pain lower (17%), mucosal dryness (12%), dyspepsia (11%)[Ref]


1. (2019) "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.